Legend Biotech Investor Relations Material

Legend Biotech Corp is a clinical-stage biopharmaceutical company, focusing on the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. The company's flagship product candidate is LCAR-B38M, a chimeric antigen receptor (CAR) therapy aimed at treating multiple myeloma (MM). Besides, Legend Biotech has developed a diverse portfolio of earlier-stage autologous CAR-T product candidates targeting a variety of cancers, including Non-Hodgkin's Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. The company is headquartered in Somerset, New Jersey, with its shares listed on the Nasdaq.